Content
11/13/2020
Newton, MA USA
Adaptilens
completed $1.6 million Seed Round funding. Investors include
Pillar VC (lead), Accanto Partners.
About
Adaptilens is the only IOL that imitates the human eye’s natural lens. We are a team of ophthalmologists, cataract specialists, scientists, and engineers with a singular focus on improving the vision and quality of life of cataract patients. We are developing an accommodating IOL with novel polymers to give patients the ability to focus not just on a single distance but on objects near, far, and in between--without the help of glasses or contact lenses.
Startup
Sector:
MedTech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
